2006
Gauthier S. (2006). Commentary on Mild Cognitive Impairment, Int Psychogeriatr, 18, 409-410.
Gauthier S. (2006). Delirium and dementia in the elderly . Dans Calhoun K. H. & Eibling D. E. (Éds.) , Geriatric Otolaryngology (pp. 603-608). Taylor & Francis.
Gauthier S. (2006). Les traitements par les inhibiteurs des cholinesterases, L’Année Gérontologique, 20, Serdi, Paris, 382-385.
Gauthier S. (2006). Current and future therapies for Alzheimer's disease and related disorders, Future Neurol, 1, 741-745.
Gauthier S. (2006). Treatment success in Alzheimer’s Disease, J Nutrition Health & Aging, 10, 242.
Gauthier S. (2006). Cholinesterase inhibitors in late-stage Alzheimer's disease, Lancet Neurol, 5(6), 468-9.
Gauthier S. (2006). Managing discontinuation syndrome in patients with dementia, J Psychiatry Neurosci, 31(1), 72.
Gauthier S. (2006). Clinical features of severe dementia: function . Dans Burns A. & Winblad B. (Éds.) , Severe Dementia (pp. 117-121). John Wiley & Sons, Ltd..
Gauthier S. (2006). Alzheimer's disease . Dans Schulz R., Noelker L., Rockwood K., Sprott R. & Schulz R. (Éds.) , The Encyclopedia of Aging (pp. 54-54). Springer Publishing Company.
Gauthier S., Herrmann N., Ferreri F., Agbokou C. (2006). Use of memantine to treat Alzheimer's disease, Cmaj, 175(5), 501-2.
Gauthier S., Joober R., Dube M. P., St-Onge J., Bonnel A., Gariepy D., Laurent S., Najafee R., Lacasse H., St-Charles L., Fombonne E., Mottron L., Rouleau G. A. (2006). Autism spectrum disorders associated with X chromosome markers in French-Canadian males, Mol Psychiatry, 11(2), 206-13.
Gauthier S., Juby A., Morelli L., Rehel B., Schecter R. (2006). A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study, Curr Med Res Opin, 22(11), 2251-65.
Gauthier S., Reisberg B., Zaudig M., Petersen R. C., Ritchie K., Broich K., Belleville S., Brodaty H., Bennett D., Chertkow H., Cummings J. L., de Leon M., Feldman H., Ganguli M., Hampel H., Scheltens P., Tierney M. C., Whitehouse P., Winblad B. (2006). Mild cognitive impairment, Lancet, 367(9518), 1262-70.
Gauthier S., Vellas B., Farlow M., Burn D. (2006). Aggressive course of disease in dementia, Alzheimers Dement, 2, 210-217.
Gruber R., Grizenko N., Schwartz G., Ben Amor L., Gauthier S., de Guzman R., Joober R. (2006). Sleep and COMT Polymorphism in ADHD Children: Preliminary Actigraphic Data, J Am Acad Child Adolesc Psychiatry, 45(8), 982-9.
Han Y. S., , Dumont Y., Quirion R. (2006). Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain, J Pharmacol Exp Ther.
Hirsch-Reinshagen V., Blain J. F., Poirier J., Wellington C. (2006). The absence of ABCA1 decreases soluble apoE levels but does not diminish amyloid deposition in two murine models of Alzheimer’s Disease, J Biol Chem, 280, 43243-43256.
Hsiung G. Y., Donald A., Grand J., Black S. E., Bouchard R. W., Gauthier S., Loy-English I., Hogan D. B., Kertesz A., Rockwood K., Feldman H. H. (2006). Outcomes of Cognitively Impaired Not Demented at 2 Years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias, Dement Geriatr Cogn Disord, 22(5-6), 413-420.
Hudon C., Belleville S., Souchay C., Gely-Nargeot M. C., Chertkow H., Gauthier S. (2006). Memory for gist and detail information in Alzheimer's disease and mild cognitive impairment, Neuropsychology, 20(5), 566-77.
Kar S., Poirier J., Guevara J., Dea D., Hawkes C., Robitaille Y., Quirion R. (2006). Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology, Neurobiol Aging, 27(2), 199-210.